This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Individual products are forecast on a global basis, as are overall segments.
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Cardiovascular therapeutic drugs technologies and global markets
1. Cardiovascular Therapeutic Drugs: Technologies and Global Markets.
Report Summary
The global cardiovascular therapeutic drug market was worth $140.7 billion in
2009, and is expected to grow by a compound annual growth rate (CAGR) of 2.7%
to $144.5 billion in 2010. This market will experience a sizable reduction in the
early portion of the forecast period, and then slowly rise to reach $139.8 billion in
2015, a CAGR of -0.7%.
The hypertension segment recorded $64.9 billion in sales in 2009. By a large
margin, hypertension is the largest segment within the cardiovascular market,
driven by a large number of billion-dollar-plus therapies. The market is expected to
grow to $65.3 billion in 2010 and experience a reduction through 2015 to $53.7
billion, a compound annual growth rate (CAGR) of -3.9%.
Treatment for hyperlipidemia recorded sales of more than $33 billion in 2009. Large
therapeutic drugs including Lipitor and Crestor comprise a high concentration of this
segment. Driven by patent expirations for Lipitor, and other drugs within this
segment, the segment will shrink to about $26 billion by 2015, a CAGR of -4.3%.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of cardiovascular therapies on a
global basis. Its aim is to provide a range of information, from detailed product
analyses within disease subsegments to overall industry trends, in order to quantify
and qualify the market for therapeutic drug products in the cardiovascular segment.
Individual products are forecast on a global basis, as are overall segments.
Forecasts and trends are developed from a cross-reference of data points, gleaned
from proprietary industry sources, company publications, industry benchmarking,
and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly,
the ability to develop an effective strategy begins with where opportunity exists and
ends with how to effectively execute to capture profit from opportunity.
The Cardiovascular Therapeutic Drug Market is the largest of any drug sector. In
addition, companies that hold patent rights to the largest drug classes have elected
to exit the sector, opening the market up to the next tier of participants.
Market growth has been spurred by the introduction of differentiated therapies due
to novel mechanism of action, such as P2Y12 inhibitors and Factor Xa inhibitors. In
2. contrast to technical innovation, patent expiry is producing a severe headwind as
evidenced by Lipitor and Plavix which are expected to drop $19 billion in one-year
sales in 2015 from 2010.
This study investigates one of the most important market drivers: the introduction
of combination therapies, which are expected to continue to contribute substantially
to market growth through the forecast period. Combination therapies for
hypertension are anticipated, as evidenced by Valturna (Novartis, Diovan and
Tekturna) and Exforge (Novartis, Diovan and amlodipine).
This report analyzes emerging markets, by disease segment. Continued growth is
expected in emerging geographies, driven by the growing middle class in emerging
countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing
market dynamic, emerging players and technologies, strategies for accessing
emerging markets, and specific disease segments and geographies in order to
allocate resources and make effective decisions.
Browse All Pharmaceuticals Market Research Reports
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2010 to 2015)
are discussed. As well, new products approved in 2009 and 2010 by the FDA, and
those products expected to be approved within the forecast period are projected.
2010 is an estimated figure, except where actual results have been reported, due to
the release timing of the report. For large markets segments such as hypertension,
hyperlipidemia, and thrombosis, specific mechanisms of action are discussed in
detail. For example, the trend of increased use of statins as a first-line therapy as
compared to beta blockers and heparin therapies is analyzed. For each core
segment within the overall market, leading products are analyzed for their
differentiation by mechanism of action. The attempt to pursue and seek approval
for PDE5 inhibitors is discussed in detail.
The report includes analysis of leading and emerging competitors in the current
worldwide cardiovascular market. Profiles of manufacturers of leading products as
well as biotechnology companies with novel products in development are analyzed
to define their specific product strategies employed. This report also assesses
companies poised to introduce products during the forecast period and discusses
how these introductions will change the face of the competitive environment. The
competitive environment is examined with a special focus on how new products and
technologies are influencing the current standard of care. Detailed profiles of
current market leaders are discussed, as well as companies with innovative
products poised to advance within the forecast period.
3. Market figures are based on revenues at the manufacturers’ level and are projected
at 2010-dollar value. Inflation is not computed into the projection figures. Trends
are assessed based on projected sales for existing products, new product
introductions, expanded indications for existing products, and projected changes in
the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category, and by company
from 2009 through 2015. The study is arranged to offer an overview of the
cardiovascular market accompanied by product, company, geography, and
mechanism of action with forecasts broken down and covered by geographic region
or country. Virtually the entire globe is covered to include prevalence data, for each
disease sub segment.
Excluded from this report are over-the-counter (OTC) medications, and other
consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency
fluctuations within the performance of revenue change. Revenue figures do not
account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
INTENDED AUDIENCE
This report is an invaluable tool for business planners, acquisitions specialists,
licensing strategists, product managers, market research analysts, investors,
investor consultants and anyone interested in the cardiovascular market, its
products, its industry participants and its future.
The importance of identifying overall market trends, product opportunities,
emerging geographies, M&A opportunities and insights that provide guidance for
sales growth or defensive moves cannot be overstated for a variety of constituents,
including:
* Established companies in the industry will benefit from the contents, including
corporate strategy, sales and marketing, business development, and R&D.
* Emerging biotechnology players in the segment must understand specific
opportunities for out-licensing, originating from the elements of differentiation of
their therapeutic drug as compared to leading, competitive, and emerging
therapies. As well, market forecasts can support investment, provided a thorough
and detailed substantiation is provided for the market forecast, as is found in this
study.
* Investment firms evaluating candidates for venture capital or hedged investments
will gain insights as to the opportunity and risks that are being encountered in the
industry, in a product and company specific analysis.
* Equity analysts are provided detailed forecasts for the next 5 years, substantiated
4. by quantitative analysis that can support further analysis to product and company
forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are
executives in companies, industry analysts, and leading medical practitioners in the
field.
Information to prepare this report was obtained from participating and emerging
companies in the cardiovascular area; American Heart Association, the National
Heart, Lung and Blood Institute and the National Heart, Lung, and Blood Institute;
articles published in medical journals such as American Heart Journal, Circulation,
Journal of Cardiovascular Pharmacology, Lancet, and others; the World Health
Organization and other government agencies; literature searches; annual reports;
10Ks; and others. Population estimates are based on those reported by the
International data base of the U.S. Census Bureau.
Current and historical revenue figures for individual products have been sourced
from company disclosures that exist in the public domain or from government
sources.
Table of Contents
CHAPTER ONE: INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
RELATED REPORTS
BCC ONLINE SERVICES
DISCLAIMER
CHAPTER TWO: SUMMARY
SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS,
THROUGH 2015 ($ MILLIONS)
SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY DISEASE
CLASS, 2007-2015 ($ MILLIONS)
5. CHAPTER THREE: OVERVIEW
CURRENT STATE OF CARDIOVASCULAR DISEASE
FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES; 2006
(DEATHS PER 100,000)
ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE
Statins
Angiotensin Receptor Blocker
Angiotensin Converting Enzyme (ACE) inhibitors
EMERGING DRUG CLASSES
P2Y12 Inhibitors and Antagonists
Factor Xa Inhibitors
Cholesterol-Ester Transfer Protein (CETP) Inhibitor
TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENT
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET
PLAVIX METABOLIZER 2C19 TRIGGERS U.S. WARNING
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR
HYPERTENSION
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT
TABLE 2 RECENTLY APPROVED DRUGS
TABLE 3 SUMMARY PIPELINE FORECAST
6. CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS
INDUSTRY STRUCTURE
TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND
SHARE, THROUGH 2010 ($ MILLIONS)
MARKET CONCENTRATION AND PRICE SENSITIVITY
TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)
MARKET TRENDS
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume
TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($ MILLIONS)
Massive Patent Expiration is a Growth Opportunity for Generics
Market Expansion via Disease Prevention is the Future of Cardio Care
Atrial Fibrillation is a Large and Emerging Disease State
Combination Therapies are Synergistic Revenue Generators
TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)
TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS ($
MILLIONS)
TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE
CARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)
CHAPTER FIVE: MARKETS BY DISEASE
7. SUMMARY OF MARKET DYNAMICS
TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS,
THROUGH 2015 ($ MILLIONS)
HYPERTENSION
PATHOPHYSIOLOGY AND PATHOGENESIS
Pathophysiology and Pathogenesis (Continued)
TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE
DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)
TREATMENT AND MANAGEMENT
TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($
MILLIONS)
Diovan/Co-Diovan
Micardis
Benicar
Norvasc
Cozaar/Hyzaar
TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH 2015 ($
MILLIONS)
TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSION
HYPERLIPIDEMIA
8. PATHOPHYSIOLOGY AND PATHOGENESIS
Genetic Factors in Hyperlipidemia
TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA (TRIGLYCERIDE
AND TOTAL CHOLESTEROL)
TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIAS
TREATMENT AND MANAGEMENT
TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010 ($
MILLIONS)
Lipitor
Crestor
Zetia
Vytorin
TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST, THROUGH 2015 ($
MILLIONS)
TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA
THROMBOSIS
PATHOPHYSIOLOGY AND PATHOGENESIS
TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($
MILLIONS)
TREATMENT AND MANAGEMENT
Plavix
9. Lovenox
TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH 2015 ($
MILLIONS)
CARDIAC FAILURE DISEASE
PATHOPHYSIOLOGY AND PATHOGENESIS
Stroke
TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
Cardiac Arrhythmias
Angina Pectoris
Myocardial Infarction (MI)
Congestive Heart Failure (CHF)
Acute Coronary Syndrome (ACS)
TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010 ($
MILLIONS)
TREATMENT AND MANAGEMENT
Vastarel
Other Drugs
TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST, THROUGH 2015 ($
MILLIONS)
OTHER CARDIOVASCULAR DISEASE
10. PATHOPHYSIOLOGY AND PATHOGENESIS
Pulmonary Hypertension
Peripheral Artery Disease (PAD)
TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL MARKET ($
MILLIONS)
TREATMENT AND MANAGEMENT
Tracleer
Other Drugs
TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST, THROUGH
2015 ($ MILLIONS)
CHAPTER SIX: MARKETS BY DRUG CLASS
SUMMARY OF MARKET DYNAMICS
TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS, 2008-2010
($ MILLIONS)
TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS,
THROUGH 2015 ($ MILLIONS)
MONOTHERAPIES
STATINS
TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($
MILLIONS)
11. Genetic Influences to Statin Efficacy
TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION CORRELATION
TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA, THROUGH
2015 ($ MILLIONS)
ANGIOTENSIN RECEPTOR BLOCKER (ARB)
TABLE 32 COMPARISON OF ARB PHARMACOKINETICS
TABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTH AND
SHARE, 2007-2010 ($ MILLIONS)
Myocardial Infarction Risk Due to ARB Inhibition
ARB Impact on Alzheimer’s Disease Risk
TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($
MILLIONS)
CALCIUM CHANNEL BLOCKERS (CCB)
TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH AND
SHARE, 2007-2010 ($ MILLIONS)
TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 ($
MILLIONS)
LOW MOLECULAR WEIGHT HEPARINS (LMWH)
TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH AND
SHARE, 2007-2010 ($ MILLIONS)
TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH 2015 ($
MILLIONS)
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS
TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND SHARE, 2007-
2010 ($ MILLIONS)
12. TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION,
THROUGH 2015 ($ MILLIONS)
P2Y12 AND FACTOR XA INHIBITORS
Effient (Prasugrel): a Leading P2Y12 Antagonist
TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010 ($
MILLIONS)
TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH AND SHARE,
2007-2010 ($ MILLIONS)
TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
COMBINATION DRUG CLASSES
CHAPTER SEVEN: MARKETS BY GEOGRAPHY
SUMMARY
TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($
MILLIONS)
METHODOLOGY
TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($
MILLIONS)
UNITED STATES
TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(U.S.)
TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(U.S.)
TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (U.S.)
WESTERN EUROPE
13. TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(WESTERN EUROPE)
TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(WESTERN EUROPE)
TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (WESTERN
EUROPE)
JAPAN
TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(JAPAN)
TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(JAPAN)
TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (JAPAN)
STRATEGIES TO ACCESS EMERGING MARKETS
EMERGING MARKETS FORECAST
BRAZIL
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(BRAZIL)
TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(BRAZIL)
TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (BRAZIL)
CHINA
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
14. PATENT CONSIDERATIONS
TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(CHINA)
TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(CHINA)
TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CHINA)
INDIA
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(INDIA)
TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(INDIA)
TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (INDIA)
RUSSIA
MARKET OVERVIEW
REGULATORY CONSIDERATIONS
PATENT CONSIDERATIONS
TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(RUSSIA)
TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(RUSSIA)
TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (RUSSIA)
SOUTH AMERICA
15. TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(SOUTH AMERICA)
TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(SOUTH AMERICA)
TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTH
AMERICA)
CARRIBEAN
TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(CARRIBEAN)
TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(CARRIBEAN)
TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(CARRIBEAN)
NORTHERN EUROPE
TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(NORTHERN EUROPE)
TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(NORTHERN EUROPE)
TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (NORTHERN
EUROPE)
CENTRAL AND EASTERN EUROPE
TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(CENTRAL & EASTERN EUROPE)
TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(CENTRAL & EASTERN EUROPE)
TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CENTRAL &
EASTERN EUROPE)
AUSTRALIA
TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(AUSTRALIA)
TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(AUSTRALIA)
16. TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(AUSTRALIA)
ASIA-OTHER
TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(ASIA-OTHER)
TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(ASIA-OTHER)
TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (ASIA-
OTHER)
MIDDLE EAST
TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(MIDDLE EAST)
TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(MIDDLE EAST)
TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (MIDDLE
EAST)
SOUTHERN AFRICA
TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015
(SOUTHERN AFRICA)
TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015
(SOUTHERN AFRICA)
TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTHERN
AFRICA)
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY FORECAST
CHAPTER EIGHT: PIPELINE ANALYSIS
TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($ MILLIONS)
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT
17. VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR
HYPERTENTION
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS, IN PARTICULAR FACTOR
XA
P2Y12 IS A PROVEN TARGET FOR MULTIPLE INDICATIONS; APPROVALS ARE
EXPECTED
APOB-100 AS A NOVEL TREATMENT FOR HYPERLIPIDEMIA
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH HDL CHOLESTEROL LEVELS
2009 APPROVALS IN CARDIOVASCULAR THERAPY
MULTAQ (DRONEDARONE) - SANOFI-AVENTIS
TABLE 93 MULTAQ SNAPSHOT
XARELTO (RIVAROXABAN) - BAYER SCHERING/J&J
TABLE 94 XARELTO SNAPSHOT
EFFIENT/EFIENT (PRASUGREL) - ELI LILLY/DAIICHI SANKYO
TABLE 95 EFFIENT SNAPSHOT
RENDIX (DABIGATRAN) - BOEHRINGER INGELHEIM
TABLE 96 RENDIX SNAPSHOT
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS
APIXABAN - BRISTOL-MYERS SQUIBB (BMS)/PFIZER
TABLE 97 APIXABAN SNAPSHOT
19. TABLE 109 BMS’ CARDIOVASCULAR PIPELINE
TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINE
CHAPTER NINE: COMPANY PROFILES
SUMMARY
TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS, 2007-2009
($ MILLIONS)
TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($ MILLIONS)
ABBOTT LABORATORIES
Business Overview
Corporate Strategy
ACTELION LTD.
Business Overview
Leading Products
Corporate Strategy
ASTELLAS PHARMA, INC.
Business Overview
Leading Products
Corporate Strategy
ASTRAZENECA
Business Overview
Leading Products
Crestor
Atacand
20. Certriad
Corporate Strategy
BAYER AG
Business Overview
Leading Products
Adalat
BRISTOL-MYERS SQUIBB COMPANY
Business Overview
Leading Products
Plavix
Apixaban
Corporate Strategy
DAIICHI SANKYO, INC. (DAIICHI SANKYO GROUP)
Business Overview
Leading Products
Benicar
Effient
Corporate Strategy
ELI LILLY & CO.
Business Overview
Leading Products
FOREST LABORATORIES, INC.
Business Overview
21. Leading Products
Benicar
Corporate Strategy
GILEAD SCIENCES, INC.
Business Overview
Leading Products
Corporate Strategy
GLAXOSMITHKLINE (GSK)
Business Overview
Leading Products
Arixtra
Corporate Strategy
MERCK & CO., INC.
Business Overview
Leading Products
Vytorin
Zetia
Cozaar
Hyzaar
Zocor
Corporate Strategy
MYLAN, INC.
Business Overview
22. Corporate Strategy
NOVARTIS
Business Overview
Leading Products
Diovan
Co-Diovan
Exforge
Corporate Strategy
PFIZER, INC.
Business Overview
Leading Products
Lipitor
Norvasc
Revatio
Corporate Strategy
SANOFI AVENTIS
Business Overview
Leading Products
Plavix
Lovenox
Multaq
Corporate Strategy
TAKEDA PHARMACEUTICAL COMPANY LIMITED
23. Business Overview
Leading Products
Blopress
Atacand and Atacand Plus
Corporate Strategy
TEVA PHARMACEUTICAL INDUSTRIES LTD
Business Overview
Leading Products
Clopidogrel
Corporate Strategy
THE MEDICINES COMPANY, INC.
Website: www.themedicinescompany.com
Business Overview
Leading Products
Angiomax
Corporate Strategy
UNITED THERAPEUTICS CORPORATION
Business Overview
Leading Products
Remodulin
Corporate Strategy
24. LIST OF TABLES
SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY
DISEASE CLASS, THROUGH 2015 ($ MILLIONS)
TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENT
TABLE 2 RECENTLY APPROVED DRUGS
TABLE 3 SUMMARY PIPELINE FORECAST
TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH
AND SHARE, THROUGH 2010 ($ MILLIONS)
TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE ($ MILLIONS)
TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS ($
MILLIONS)
TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE ($ MILLIONS)
TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS
($ MILLIONS)
TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE
CARDIOVASCULAR SEGMENT, 2009 AND 2010 ($ MILLIONS)
TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE
CLASS, THROUGH 2015 ($ MILLIONS)
TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE
DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)
TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 ($
25. MILLIONS)
TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH
2015 ($ MILLIONS)
TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSION
TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA
(TRIGLYCERIDE AND TOTAL CHOLESTEROL)
TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIAS
TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010
($ MILLIONS)
TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST,
THROUGH 2015 ($ MILLIONS)
TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA
TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 ($
MILLIONS)
TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH
2015 ($ MILLIONS)
TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010
($ MILLIONS)
TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST,
THROUGH 2015 ($ MILLIONS)
TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL
MARKET ($ MILLIONS)
26. TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST,
THROUGH 2015 ($ MILLIONS)
TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS,
2008-2010 ($ MILLIONS)
TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS,
THROUGH 2015 ($ MILLIONS)
TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-
2010 ($ MILLIONS)
TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION
CORRELATION
TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA,
THROUGH 2015 ($ MILLIONS)
TABLE 32 COMPARISON OF ARB PHARMACOKINETICS
TABLE 33 ARB CURRENT MARKET FOR HYPERTYENSION, GROWTH
AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH
2015 ($ MILLIONS)
TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH
AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH
2015 ($ MILLIONS)
TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH
AND SHARE, 2007-2010 ($ MILLIONS)
27. TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH
2015 ($ MILLIONS)
TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND
SHARE, 2007-2010 ($ MILLIONS)
TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION,
THROUGH 2015 ($ MILLIONS)
TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007-2010
($ MILLIONS)
TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 ($ MILLIONS)
TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH
AND SHARE, 2007-2010 ($ MILLIONS)
TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 ($
MILLIONS)
TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 ($
MILLIONS)
TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 ($
MILLIONS)
TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (U.S.)
TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (U.S.)
TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(U.S.)
28. TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (WESTERN EUROPE)
TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (WESTERN EUROPE)
TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(WESTERN EUROPE)
TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (JAPAN)
TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (JAPAN)
TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(JAPAN)
TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (BRAZIL)
TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (BRAZIL)
TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(BRAZIL)
TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (CHINA)
TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (CHINA)
TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
29. (CHINA)
TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (INDIA)
TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (INDIA)
TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(INDIA)
TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (RUSSIA)
TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (RUSSIA)
TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(RUSSIA)
TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (SOUTH AMERICA)
TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (SOUTH AMERICA)
TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(SOUTH AMERICA)
TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (CARRIBEAN)
TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (CARRIBEAN)
30. TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(CARRIBEAN)
TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (NORTHERN EUROPE)
TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (NORTHERN EUROPE)
TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(NORTHERN EUROPE)
TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (CENTRAL & EASTERN EUROPE)
TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (CENTRAL & EASTERN EUROPE)
TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(CENTRAL & EASTERN EUROPE)
TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (AUSTRALIA)
TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
2015 (AUSTRALIA)
TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015
(AUSTRALIA)
TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH
2015 (ASIA-OTHER)
TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH
32. TABLE 99 CERTRIAD SNAPSHOT
TABLE 100 LCZ696 SNAPSHOT
TABLE 101 EDOXABAN (DU-176B) SNAPSHOT
TABLE 102 SCH530348 SNAPSHOT
TABLE 103 TYRISA SNAPSHOT
TABLE 104 BETRIXABAN SNAPSHOT
TABLE 105 PFIZER’S CARDIOVASCULAR PIPELINE
TABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINE
TABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINE
TABLE 108 MERCK’S CARDIOVASCULAR PIPELINE
TABLE 109 BMS’ CARDIOVASCULAR PIPELINE
TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINE
TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS,
2007-2009 ($ MILLIONS)
TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 ($
MILLIONS)
LIST OF FIGURES
SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY
DISEASE CLASS, 2007-2015 ($ MILLIONS)
FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES;
2006 (DEATHS PER 100,000)
33. About Us:
ReportsnReports is an online library of over 100,000+ market research reports and
in-depth market research studies & analysis of over 5000 micro markets. We
provide 24/7 online and offline support to our customers. Get in touch with us for
your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page:
http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog